Mason Eye Institute, University of Missouri, Columbia, MO.
Biostatistics Center, The George Washington University, Washington, DC.
Diabetes Care. 2019 May;42(5):875-882. doi: 10.2337/dc18-2308. Epub 2019 Mar 4.
The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy reduced the development and progression of retinopathy in type 1 diabetes (T1D) compared with conventional therapy. The Epidemiology of Diabetes Interventions and Complications (EDIC) study observational follow-up showed persistent benefits. In addition to glycemia, we now examine other potential retinopathy risk factors (modifiable and nonmodifiable) over more than 30 years of follow-up in DCCT/EDIC.
The retinopathy outcomes were proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), and ocular surgery. The survival (event-free) probability was estimated using the Kaplan-Meier method. Cox proportional hazards models assessed the association between risk factors and subsequent risk of retinopathy. Both forward- and backward-selection approaches determined the multivariable models.
Rate of ocular events per 1,000 person-years was 12 for PDR, 14.5 for CSME, and 7.6 for ocular surgeries. Approximately 65%, 60%, and 70% of participants remained free of PDR, CSME, and ocular surgery, respectively. The greatest risk factors for PDR in descending order were higher mean HbA, longer duration of T1D, elevated albumin excretion rate (AER), and higher mean diastolic blood pressure (DBP). For CSME, risk factors, in descending order, were higher mean HbA, longer duration of T1D, and greater age and DBP and, for ocular surgeries, were higher mean HbA, older age, and longer duration of T1D.
Mean HbA was the strongest risk factor for the progression of retinopathy. Although glycemic control is important, elevated AER and DBP were other modifiable risk factors associated with the progression of retinopathy.
糖尿病控制与并发症试验(DCCT)表明,与常规治疗相比,强化治疗可降低 1 型糖尿病(T1D)患者的视网膜病变的发生和进展。糖尿病并发症的流行病学(EDIC)研究的观察性随访显示了持续的益处。除了血糖水平外,我们现在还在超过 30 年的 DCCT/EDIC 随访中检查其他潜在的视网膜病变危险因素(可改变和不可改变)。
视网膜病变的结局包括增殖性糖尿病视网膜病变(PDR)、临床显著黄斑水肿(CSME)和眼部手术。使用 Kaplan-Meier 法估计视网膜病变的无事件生存(无事件)概率。Cox 比例风险模型评估了危险因素与随后的视网膜病变风险之间的关联。前向和后向选择方法确定了多变量模型。
每 1000 人年眼部事件发生率分别为 PDR 12 次、CSME 14.5 次和眼部手术 7.6 次。大约 65%、60%和 70%的参与者分别未发生 PDR、CSME 和眼部手术。PDR 的最大危险因素按降序排列依次为较高的平均 HbA、较长的 T1D 病程、较高的白蛋白排泄率(AER)和较高的平均舒张压(DBP)。对于 CSME,按降序排列的危险因素分别为较高的平均 HbA、较长的 T1D 病程、较大的年龄和 DBP,对于眼部手术,危险因素分别为较高的平均 HbA、较大的年龄和较长的 T1D 病程。
平均 HbA 是视网膜病变进展的最强危险因素。尽管血糖控制很重要,但升高的 AER 和 DBP 是其他与视网膜病变进展相关的可改变危险因素。